A peptide may include a sequence having 80% or more amino acid identity with the amino acid sequence of SEQ ID NO. 1, i.e., RPSX.sub.1CNLPVKPGPCX.sub.2GFFSAFYYSQKX.sub.3NKCHSFTYGGCAGNANRFSTX.sub.4EKCRRTC X.sub.5X.sub.6, wherein, X.sub.1 is the amino acid residue F or G, X.sub.2 is any amino acid residue, except a basic amino acid residue, X.sub.3 is the amino acid residue T or D, X.sub.4 is the amino acid residue I, L, or E, (i) X.sub.5 is V and X.sub.6 is G or (ii) X.sub.5 is G and X6 is V, and the amino acid located at position 39 is A. Such peptides may have various diagnostic and therapeutic uses.

The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a lung cancer, and especially a non-small call lung cancer (NSCLC), and even more especially a NSCLC selected in a group comprising epidermoid NSCLC, adenocarcinoma NSCLC, large cells NSCLC and squamous cell carcinoma NSCLC and neuroendocrine NSCLC.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

A chemical sensor for detecting a target substance in a gas sample, including a membrane; and an olfactory receptor fragment which is fixed to the membrane. The chemical sensor optionally includes a source electrode connected to one end of the membrane; and a drain electrode connected to the other end of the membrane, in which the membrane is a graphene.

Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).

A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.

A method of determining whether a subject has a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e.g. Angiotensin converting enzyme inhibitor (ACE inhibitor), Angiotensin Receptor Blocker (ARB), Beta-Adrenoreceptor Blocker (Beta-blocker) and/or statins) by determining the level of hGH, and/or its isoforms in a blood sample of said subject and comparing the determined level of hGH, and/or its isoforms in said blood sample with a pre-determined threshold.

The present invention provides an in vitro method for detecting the presence of neutralizing antibodies against recombinant human insulin (rHI) in human serum. It also provides a kit for an in vitro method of detection of the presence of recombinant human insulin (rHI) neutralizing antibodies.

An object of the present invention is to demonstrate the existence of a heterodimer of somatostatin receptor subtype 1 (SSTR1) and somatostatin receptor subtype 4 (SSTR4) and also to provide a method for screening a factor that binds to such a heterodimer and the heterodimer that can be used in the screening method. A transformant expressing a heterodimer of somatostatin receptor subtype 1 and somatostatin receptor subtype 4, into which DNA encoding somatostatin receptor subtype 1 and DNA encoding somatostatin receptor subtype 4 have been introduced. A method for screening a compound that interacts with a heterodimer of somatostatin receptor subtype 1 and somatostatin receptor subtype 4, comprising selecting the compound that interacts with the heterodimer from test compounds.